Abstract
Neuroblastoma is the most common extracranial solid malignancy in children but rarely described in adults, being 10% of all cases diagnosed after the first decade of life. We report a 23 year-old black woman with a mass at paravertebral region of T3-T5, multiple lesions in vertebral bodies and expanding skull-brain lesion at the right parietal region. Immunohistochemical analysis (negative for CD99, CD20, CD3 and desmin; and positive chromogranin, synaptophysin and NB84) confi rmed the diagnosis of neuroblastoma. The patient was submitted to 12 cycles of chemotherapy receiving VAC (vincristine/doxorubicin/cyclophosphamide) interspersed with ICE (ifosfamide/mesna/etoposide) and doxorubicin was replaced by actinomycin in the 7th cycle. She had good tolerance to this therapy, and has been clinically stable.
MeSH terms
-
Antineoplastic Combined Chemotherapy Protocols / administration & dosage
-
Antineoplastic Combined Chemotherapy Protocols / therapeutic use
-
Biopsy
-
Bone Neoplasms / secondary
-
Brain Neoplasms / secondary*
-
Brain Neoplasms / therapy
-
Carboplatin / administration & dosage
-
Cyclophosphamide / administration & dosage
-
Doxorubicin / administration & dosage
-
Etoposide / administration & dosage
-
Female
-
Humans
-
Ifosfamide / administration & dosage
-
Mesna / administration & dosage
-
Neuroblastoma / pathology*
-
Neuroblastoma / therapy
-
Spinal Cord Compression / etiology*
-
Spinal Cord Neoplasms / secondary*
-
Spinal Cord Neoplasms / therapy
-
Thoracic Vertebrae
-
Vincristine / administration & dosage
-
Young Adult
Substances
-
Vincristine
-
Etoposide
-
Doxorubicin
-
Cyclophosphamide
-
Carboplatin
-
Mesna
-
Ifosfamide
Supplementary concepts
-
CAV protocol
-
ICE protocol 5